Design and development of antisense drugs

Expert Opinion on Drug Discovery

Volumn 3, Issue 10, 2008, Pages 1189-1207

  Malik, Ravinder ^a   Roy, Ipsita ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

AIDS; Cancer; Fomivirsen; Gene therapy; Nucleic acids; Oblimersen

Indexed keywords

ANTIRETROVIRUS AGENT; ANTISENSE OLIGONUCLEOTIDE; CANTIDE ANTISENSE; CELECOXIB; CISPLATIN; DACARBAZINE; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; GLIPIZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; ISIS 113715; ISIS 147764; ISIS 301012; ISIS 333611; ISIS 377131; LENTIVIRUS VECTOR; LIPOSOME; METFORMIN; METHYLPHOSPHONIC ACID; MIPOMERSEN; OBLIMERSEN; OLIGONUCLEOTIDE; ORAL ANTIDIABETIC AGENT; PLACEBO; PRO 051; SMALL INTERFERING RNA; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VRX 496;

ABSENCE OF SIDE EFFECTS; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; BLOOD TOXICITY; CARDIOVASCULAR DISEASE; CHEMICAL MODIFICATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DEGENERATIVE DISEASE; DIABETES MELLITUS; DRUG BINDING; DRUG DESIGN; DRUG EFFICACY; DRUG FEVER; DRUG INDICATION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GENE SEQUENCE; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; LIPOSOMAL DELIVERY; MONOTHERAPY; NEOPLASM; NEUTROPENIA; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OBESITY; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SIDE EFFECT; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; VIRAL GENE DELIVERY SYSTEM;

EID: 55049111537     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.3.10.1189     Document Type: Review

References (130)

1. Rayburn ER, Zhang R. Antisense, RNAi and gene silencing strategies for therapy: mission possible or impossible? Drug Discov Today 2008;13(11-12):513-21
2. Kaur G, Roy I. Therapeutic applications of aptamers. Expert Opin Investig Drugs 2008;17(1):43-60
3. Tan EL, Marcus KF, Poh CL. Development of RNA interference (RNAi) as potential antiviral strategy against enterovirus 70. J Med Virol 2008;80(6):1025-32
4. Dass CR, Choong PF, Khachigian LM. DNAzyme technology and cancer therapy: cleave and let die. Mol Cancer Ther 2008;7(2):243-51
5. Paterson BM, Roberts BE, Kuff EL. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci USA 1977;74(10):43704
6. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 1978;75(1):280-4
7. Sarin PS, Agrawal S, Civeira MP, et al. Inhibition of acquired immunodeficiency syndrome virus by oligodeoxynucleoside methylphosphonates. Proc Natl Acad Sci USA 1988;85(20):7448-51
8. Stenton GR, Ulanova M, Dery RE, et al. Inhibition of allergic inflammation in the airways using aerosolized antisense to Syk kinase. J Immunol 2002;169(2):1028-36
9. Gauvreau GM, Boulet LP, Cockcroft DW, et al. Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med 2008;177(9):952-8
10. Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exp Physiol 2008;93(1):27-42
11. Huber LC, Distler O, Gay RE, Gay S. Antisense strategies in degenerative joint diseases: sense or nonsense? Adv Drug Deliv Rev 2006;58(2):285-99
12. Yildiz D, Oztas H, Hilal Ates B. Antisense oligonucleotides and prevention of tumor growth: a different approach and proposal for a new method. Med Hypotheses 2005;64(2):328-32
13. Geary RS, Bradley JD, Watanabe T, et al. Lack of pharmacokinetic interaction for ISIS 113715, a 2′-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone. Clin Pharmacokinet 2006;45(8):789-801
14. Sinck I, Richer D, Howard J, et al. In vitro dimerization of human immunodeficiency virus type 1 (HIV-1) spliced RNAs. RNA 2007;13(12):2141-50
15. Spurgers KB, Sharkey CM, Warfield KL, Bavari S. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. Antiviral Res 2008;78(1):26-36
16. Aichberger KJ, Mayerhofer M, Gleixner KV, et al. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412. Blood 2007;109(7)-3031-41
17. Thompson JD. Applications of antisense and siRNAs during preclinical drug development. Drug Discov Today 2002;7(17):912-7
18. Orr RM. Technology evaluation: fomivirsen, Isis pharmaceuticals Inc/CIBA vision. Curr Opin Mol Ther 2001;3(3):288-94
19. De Smet MD, Meenken CJ, Van Den Horn GJ. Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis. Ocul Immunol Inflamm 1999;7(3-4):189-98
20. Pan WH, Clawson GA. Antisense applications for biological control. J Cell Biochem 2006;98(1):14-35
21. Wagner EG, Simons RW. Andsense RNA control in bacteria, phages, and plasmids. Ann Rev Microbiol 1994;48:713-42
22. Eguchi Y, Itoh T, Tomizawa J. Antisense RNA. Ann Rev Biochem 1991;60:631-52
23. Kumar M, Carmichael GG. Antise-RNA: function and fate of duplex RNA in cells of higher eukaryotes. Microbiol Mol Biol Rev 1998;62(4):1415-34
24. Werner A, Berdal A. Natural antisense transcripts: sound or silence? Physiol Genomics 2005;23(2):125-31
25. Kumar M, Carmichael GG. Nuclear antisense RNA induces extensive adenosine modifications and nuclear retention of target transcripts. Proc Natl Acad Sci USA 1997;94(8):3542-7
26. Aartsma-Rus A, Van Ommen GJ. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 2007;13(10):1609-24
27. Sazani P, Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest 2003;112(4):481-6
28. sturino JM, Klaenhammer TR. Antisense RNA targeting of primase interferes with bacteriophage replication in Streptococcus thermophilus. Appl Environ Microbiol 2004;70(3):1735-43
29. Stein CA, Cheng YC. Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science 1993;261(5124):1004-12
30. Gewirtz AM, Sokol DL, Ratajczak MZ. Nucleic acid therapeutics: state of the art and future prospects. Blood 1998;92(3):712-36
31. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004;431(7006):343-9
32. Pan WH, Clawson GA. Identifying accessible sites in RNA. the first step in designing antisense reagents. Curr Med Chem 2006;13(25):3083-103
33. Forsyth RA, Haselbeck RJ, Ohlsen KL, et al. A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol Microbiol 2002;43(6):1387-400
34. Sczakiel G, Homann M, Rittner K. Computer-aided search for effective antisense RNA target sequences of the human immunodeficiency virus type 1. Antisense Res Dev 1993;3(1):45-52
35. Zuker M. On finding all suboptimal foldings of an RNA molecule. Science 1989;244(4900):48-52
36. Sohail M, Southern EM. Selecting optimal antisense reagents. Adv Drug Deliv Rev 2000;44(1):23-34
37. Milner N, Mir KU, Southern EM. Selecting effective antisense reagents on combinatorial oligonucleotide arrays. Nat Biotechnol 1997;15(6):537-41
38. Mir KU, Southern EM. Determining the influence of structure on hybridization using oligonucleotide arrays. Nat Biotechnol 1999;17(8):788-92
39. Ho SP. Bao Y, Lesher T, et al. Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries. Nat Biotechnol 1998;16(1):59-63
40. Walton SP, Stephanopoulos GN, Yarmush ML, Roth CM. Thermodynamic and kinetic characterization of antisense oligodeoxynucleotide binding to a structured mRNA. Biophys J 2002;82(1 Pt 1):366-77
41. Gupta KC. Antisense oligodeoxynucleotides provide insight into mechanism of translation initiation of two Sendai virus mRNAs. J Biol Chem 1987;262(16):7492-6
42. Dias N, Stein CA. Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 2002;1(5):347-55
43. Roberts J, Palma E, Sazani P, et al. Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. Mol Ther 2006;14(4):471-5
44. Bennett CF, Cowsert LM. Application of antisense oligonucleotides for gene functionalization and target validation. Curr Opin Mol Ther 1999;1(3):359-71
45. Cramer H, Okicki JR, Kuang M, Xu Z. Targeted therapy of respiratory syncytial virus by 2-5A antisense. Nucleosides Nucleotides Nucleic Acids 2005;24(5-7):497-501
46. Maier TJ, Schilling K, Schmidt R, et al. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem Pharmacol 2004;67(8):1469-78
47. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 2002;292(3):587-92
48. Perez DE, Castro I, De Carcer G, Malumbres M. A census of mitotic cancer genes: new insights into tumor cell biology and cancer therapy. Carcinogenesis 2007;28(5):899-912
49. Li W, Liu X, Wang W, et al. Effects of antisense RNA targeting of ODC and AdoMetDC on the synthesis of polyamine synthesis and cell growth in prostate cancer cells using a prostatic androgen-dependent promoter in adenovirus. Prostate 2008;67(12):1354-61
50. Marton MJ, Derisi JL, Bennett HA, et al. Drug target validation and identification of secondary drug target effects using DNA microarrays. Nat Med 1998;4(11):1293-301
51. Mukai S, Kondo Y, Koga S, et al. 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res 2000;60(16):4461-67
52. Du QY, Wang XB, Chen XJ, et al. Antitumor mechanism of antisense cantide targeting human telomerase reverse transcriptase. World J Gastroenterol 2003;9(9):2030-5
53. Yang Y, Lv QJ, Du QY, et al. Combined effects of cantide and chemotherapeutic drugs on inhibition of tumor cells' growth in vitro and in vivo. World J Gastroenterol 2005;11(16):2491-6
54. Yang D, Ling Y, Almazan M. Tumor regression of human breast carcinomas by combination therapy of anti-bcl2- antisense oligonucleotide and chemotherapeutic drugs. Proc Am Assoc Cancer Res 1999;40:729
55. Rudin CM, Otterson GA, Mauer AM, et al. A pilot trial of G3139, a bcl-2 antisense oligonucleotide and paclitaxel in patients with chemorefractory small-cell lung cancer. Ann Oncol 2002;13(4):539-45
56. Badros AZ, Goloubeva O, Rapoport AP, et al. Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients. J Clin Oncol 2005;23(18):4089-99
57. Lai JC, Brown BD, Voskresenskiy AM, et al. Comparison of D-G3139 and its enantiomer L-G3139 in melanoma cells demonstrates minimal in vitro but dramatic in vivo chiral dependency. Mol Ther 2007;15(2):270-8
58. Marshall J, Chen H, Yang D, et al. A phase I trial of a Bcl-2 antisense (G3139) and weekly docetaxel in patients with advanced breast cancer and other solid tumors. Ann Oncol 2004;15(8):1274-83
59. Bedikian AY, Millward M, Pehamberger H, et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 2006;24(29):4738-45
60. Chadwick DR, Lever AM. Antisense RNA sequences targeting the 5′ leader packaging signal region of human immunodeficiency virus type-1 inhibits viral replication at post-transcriptional stages of the life cycle. Gene Ther 2000;7(16):1362-8
61. Lu X, Yu Q, Binder GK, et al. Antisense-mediated inhibition of human immunodeficiency virus (HIV) replication by use of an HIV type 1-based vector results in severely attenuated mutants incapable of developing resistance. J Virol 2004;78(13):7079-88
62. Levine BL, Humeau LM, Boyer J, et al. Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci USA 2006;103(46):17372-7
63. Akdim F, Stroes ES, Kastelein JJ. Antisense apolipoprotein B therapy: where do we stand? Curr Opin Lipidol 2007;18(4):397-400
64. Crooke RM, Graham MJ, Lemonidis KM, et al. An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis. J Lipid Res 2005;46(5):872-84
65. Athyros VG, Kakafika AI, Tziomalos K, er al. Antisense technology for the prevention or the treatment of cardiovascular disease: the next blockbuster? Expert Opin Investig Drugs 2008;17(7):969-72
66. Peng B, Andrews J, Nestorov I, et al. Tissue distribution and physiologically based pharmacokinetics of antisense phosphorothioate oligonucleotide ISIS 1082 in rat. Antisense Nucleic Acid Drug Dev 2001;11(1):15-27
67. Wu F, Yngve U, Hedberg E, et al. Distribution of (76)Br-labeled antisense oligonucleotides of different length determined ex vivo in rats. Eur J Pharm Sci 2000;10(3):179-86
68. Miller TM, Smith RA, Kordasiewicz H, Kaspar BK. Gene-targeted therapies for the central nervous system. Arch Neurol 2008;65(4):447-51
69. Smith RA, Miller TM, Yamanaka K, et al. Antisense oligonucleotide therapy for neurodegenerative disease. J Clin Invest 2006;116(8):2290-6
70. Aartsma-RUS A, Kaman WE, Weij R, et al. Exploring the frontiers of therapeutic exon skipping for duchenne muscular dystrophy by double targeting within one or multiple exons. Mol Ther 2006;14(3):401-7
71. Van Deutekom JC, Janson AA, Ginjaar IB, et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007;357(26):2677-86
72. Wheeler TM, Lueck JD, Swanson MS, et al. Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy. J Clin Invest 2007;117(12):3952-7
73. Takeshima Y, Yagi M, Wada H, et al. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy. Pediatr Res 2006;59(5):690-4
74. Esau CC. Inhibition of microRNA with antisense oligonucleotides. Methods 2008;44(1):55-60
75. Corney DC, Nikitin AY. MicroRNA and ovarian cancer. Histol Histopathol 2008;23(9):1161-9
76. Si ML, Zhu S, Wu H, et al. miR-21-mediated tumor growth. Oncogene 2007;26(19):2799-803
77. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449(7163):682-8
78. Negrini M, Calin GA. Breast cancer metastasis: a microRNA story. Breast Cancer Res 2008;10(2):203
79. Xiao J, Yang B, Lin H, et al. Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol 2007;212(2):285-92
80. Roth CM. Molecular and cellular barriers limiting the effectiveness of antisense oligonucleotides. Biophys J 2005;89(4):2286-95
81. Ye Z, Houssein HS, Mahato RI. Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides 2007;17(4):349-404
82. Shi F, Hoekstra D. Effective intracellular delivery of oligonucleotides in order to make sense of antisense. J Control Release 2004;97(2):189-209
83. Chan JH, Lim S, Wong WS. Antisense oligonucleotides: from design to therapeutic application. Clin Exp Pharmacol Physiol 2006;33(5-6):533-40
84. Miyake H, Hara I, Fujisawa M, Gleave ME. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer. Expert Opin Investig Drugs 2006;15(5):507-17
85. Stein CA. Two problems in antisense biotechnology: in vitro delivery and the design of antisense experiments. Biochim Biophys Acta 1999;1489(1):45-52
86. Jearawiriyapaisarn N, Moulton HM, Buckley B, et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 2008;16(9):1624-9
87. Graziewicz MA, Tarrant TK, Buckley B, et al. An endogenous TNF-alpha antagonist induced by splice-switching oligonucleotides reduces inflammation in hepatitis and arthritis mouse models. Mol Ther 2008;16(7):1316-22
88. Graham MJ, Crooke ST, Monteith DK, et al. In vivo distribution and metabolism of a phosphorothioate oligonucleotide within rat liver after intravenous administration. J Pharmacol Exp Ther 1998;286(1):447-58
89. Ma CH, Sun WS, Tian PK, et al. A novel HBV antisense RNA gene delivery system targeting hepatocellular carcinoma. World J Gastroenterol 2003;9(3):463-7
90. Sokolova V, Epple M. Inorganic nanoparticles as carriers of nucleic acids into cells. Angew Chem Int Ed Engl 2008;47(8):1382-95
91. Luo D, Saltzman WM. Synthetic DNA delivery systems. Nat Biotechnol 2000;18(1):33-7
92. Tari AM, Tucker SD, Deisseroth A, Lopez-Berestein G. Liposomal delivery of methylphosphonate antisense oligodeoxynucleotides in chronic myelogenous leukemia. Blood 1994;84(2):601-7
93. Dufes C, Uchegbu IF, Schatzlein AG. Dendrimers in gene delivery. Adv Drug Deliv Rev 2005;57(15):2177-202
94. Nakase I, Niwa M, Takeuchi T, et al. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 2004;10(6):1011-22
95. Lebleu B, Moulton HM, Abes R, et al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev 2008;60(4-5):517-29
96. Moreira JN, Santos A, Moura V, et al. Non-viral lipid-based nanoparticles for targeted cancer systemic gene silencing. J Nanosci Nanotechnol 2008;8(5):2187-204
97. Spiller DG, Tidd DM. Nuclear delivery of antisense oligodeoxynucleotides through reversible permeabilization of human leukemia cells with streptolysin O. Antisense Res Dev 1995;5(1):13-21
98. Boussif O, Lezoualc'h F, Zanta MA, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995;92(16):7297-301
99. Yoo H, Juliano RL. Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers. Nucleic Acids Res 2000;28(21):4225-31
100. Graham FL, Van Der EB AJ. A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 1973;52(2):456-67
101. Wu-Pong S, Weiss TL, Hunt CA. Calcium dependent cellular uptake of a c-myc antisense oligonucleotide. Cell Mol Biol 1994;40(6):843-50
102. Kakizawa Y, Furukawa S, Kataoka K. Block copolymer-coated calcium phosphate nanoparticles sensing intracellular environment for oligodeoxynucleotide and siRNA delivery. J Control Release 2004;97(2):345-56
103. Jordan M, Schallhorn A, Wurm FM. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res 1996;24(4):596-601
104. Sokolova W, Radtke I, Heumann R, Epple M. Effective transfection of cells with multi-shell calcium phosphate-DNA nanoparticles. Biomaterials 2006;27(16):3147-53
105. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452(7187):591-7
106. Yang Z, Stratton C, Francis PJ, et al. Toll-like receptor 3 and geographic atrophy in age-related macular degeneration. N Engl J Med 2008; doi:10.1056/NEJMoa0802437
107. Putnam D, Gentry CA, Pack DW, Langer R. Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci USA 2001;98(3):1200-05
108. Plank C, Oberhauser B, Mechtler K, et al. The influence of endosome-disruptive peptides on gene transfer using synthetic virus-like gene transfer systems. J Biol Chem 1994;269(17):12918-24
109. Denti MA, Incitti T, Sthandier O, et al. Long-term benefit of adeno-associated virus/antisense-mediated exon skipping in dystrophic mice. Hum Gene Ther 2008;19(6):601-8
110. Kurreck J. Antisense technologies: improvement through novel chemical modifications. Eur J Biochem 2003;270(8):1628-44
111. Vitravene Study Group: a randomized controlled clinical trial of intravitreous fomivirsen for treatment of newly diagnosed peripheral cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol 2002;133(4):467-74
112. Available from: www.aknylam.com
113. Zheng R. Technology evaluation: GEM-92, Hybridon Inc. Curr Opin Mol Ther 1999;1(4):521-3
114. Available from: www.enzo.com
115. Available from: www.adviral.com
116. Anderson J, Li MJ, Palmer B, et al. Safety and efficacy of a lentiviral vector containing three anti-HIV genes-CCR5 ribozyme, tat-rev SiRNA, and TAR decoy - in SCID-hu mouse-derived T cells. Mol Ther 2007;15(6):1182-8
117. Pawlotsky JM, Chevaliez S, Mchutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007;132(5):1979-98
118. Mchutchison JG, Bartenschlager I, Patel K, Pawlotsky JM. The face of future hepatitis C antiviral drug development: recent biological and virologic advances and their translation to drug development and clinical practice. J Hepatol 2006;44(2):411-21
119. Available from: www.migenix.com
120. Kahan BD, Stepkowski S, Kilic M, et al. Phase I and phase II safety and efficacy trial of intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302) for the prevention of acute allograft rejection. Transplantation 2004;78(6):858-63
121. Devi GR, Beer TM, Corless CL, et al. In vivo bioavailabitity and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin Cancer Res 2005;11(10):3930-8
122. Schlingensiepen KH, Schlingensiepen R, Steinbrecher A, et al. Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009. Cytokine Growth Factor Rev 2006;17(1-2):129-39
123. Available from: www.isispharm.com
124. Available from: www.antisense.com
125. Paz-Ares L, Douillard JY, Koralewski P, et al. Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2006;24(9):1428-34
126. Azad RF, Brown-Driver V, Buckheit RW JR, Anderson KP. Antiviral activity of a phosphorothioate oligonucleotide complementary to human cytomegalovirus RNA when used in combination with antiviral nucleoside analogs. Antiviral Res 1995;28(2):101-11
127. Xu Z, Kuang M, Okicki JR, et al. Potent inhibition of respiratory syncytial virus by combination treatment with 2-5A antisense and ribavirin. Antiviral Res 2004;61(3):195-206
128. Marcucci G, Byrd JC, Dai G, et al. Phase I and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003;101(2):425-32
129. Mita MM, Ochoa L, Rowinsky EK, et al. A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer. Ann Oncol 2006;17(2):313-21
130. Berg RW, Ferguson PJ, Vincent MD, Koropatnick DJ. A "combination oligonucleotide" antisense strategy to downregulate thymidylate synthase and decrease tumor cell growth and drug resistance. Cancer Gene Ther 2003;10(4):278-86